當前位置：   首頁 > 需求大廳

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]

需要Furazolidone《 BP2019 》的電子版本。   [更多]

求購纈沙坦膠囊“Valsartan Capsules”《 BP2017 》的英國藥典標準全文一份.最好有中文翻譯   [更多]

Hydrocortisone Hydrogen Succinate   [更多]

需要菖麻熄風片質(zhì)量標準，國家標準YBZ00542014   [更多]

需要完成掃面版本   [更多]

我們公司有制劑研發(fā)項目需要找合適的CRO公司，希望大家可以推薦，一旦我們公司確認各方面實力符合我們要求每推薦成功一家可以提供100元現(xiàn)金獎勵   [更多]

文獻標題及相關(guān)內(nèi)容： 1. In vitro and in vivo metabolism of rimonabant (SR-141716), a cannabinoid (CB1) receptor antagonist 2. 各種動物およびヒトにおける LFP83 の體內(nèi)動態(tài) 3. LFP83靜脈內(nèi)投與によるラット分布, 代謝および排泄 4. 34 - Disorders of Blood Cell Production in Clinical Oncology 5. Predictive evaluation of pharmaceutical properties of direct compression tablets containing theophylline anhydrate during storage at high humidity by near-infrared spectroscopy   [更多]

“Hydrazine sulfate.”《 EP9.2 》的藥典標準一份，包括詳細的檢測方法。   [更多]